Observational Study of Biphasic Insulin Aspart 30 Alone or in Combination With Oral Hypoglycaemic Agents in Subjects With Type 2 Diabetes

Novo Nordisk A/S33,010 enrolled

Overview

This study is conducted in Africa, Asia and Europe. The aim of this study is to investigate biphasic insulin aspart 30 (NovoMix® 30) alone or in combination with oral hypoglycaemic agent (OHA) for type 2 diabetes management in routine clinical practice.

Study Type

OBSERVATIONAL

Enrollment

33,010

Conditions

Diabetes Diabetes Mellitus, Type 2

Interventions

biphasic insulin aspart 30DRUG

The insulin dose and regimen was individualised at the physician's discretion

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with type 2 diabetes whose glycaemia was not optimally controlled with current therapy

Locations (1)

Novo Nordisk Investigational Site

Seoul, South Korea

Outcomes

Primary Outcomes

Change in HbA1c (glycosylated haemoglobin)

Secondary Outcomes

Change in post prandial glucose (PPG)

Change in fasting glucose (FG)

Difference in prandial glucose increment (PGI)

Incidence of hypoglycaemic episodes

Adverse drug reactions (ADR)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.